Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 7.84 percent decrease over losses of $(0.51) per share from the same period last year.
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here’s Why
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership.
